Arquitos Capital Partners had a stellar year in 2025, returning 82.1% net of fees, far surpassing the Russell 2000’s 12.8% gain. The firm noted a shift towards established businesses in the market, with a concentrated approach and disciplined risk management driving performance, detailed in their Q4 2025 investor letter.

One of Arquitos Capital Partners’ highlighted stocks in Q4 2025 was Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company specializing in rare cardiopulmonary disease therapies. Liquidia Corporation saw a 5.56% one-month return, with shares trading between $11.26 and $46.67 over the last 52 weeks, closing at approximately $39.04 per share on February 13, 2026.

Liquidia Corporation (NASDAQ:LQDA) was a key contributor to Arquitos Capital Partners’ success in 2025, with shares rising from $11.76 to $34.49. The firm primarily holds long-dated call options that are currently in the money, showcasing the stock’s positive momentum in the market.

Despite not being among the 30 most popular stocks among hedge funds, Liquidia Corporation (NASDAQ:LQDA) saw 42 hedge fund portfolios holding the stock at the end of Q3 2025, emphasizing its potential as an investment. While the stock holds promise, there are other AI stocks with the potential for higher returns in a shorter timeframe, as detailed in a separate article.

Read more at Yahoo Finance: Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling